Profile data is unavailable for this security.
About the company
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.
- Revenue in USD (TTM)90.22m
- Net income in USD-22.66m
- Incorporated2003
- Employees159.00
- LocationAlimera Sciences IncSTE 290, 6120 WINDWARD PARKWAYALPHARETTA 30005United StatesUSA
- Phone+1 (678) 990-5740
- Fax+1 (678) 990-5744
- Websitehttps://alimerasciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mediwound Ltd | 19.85m | -12.75m | 151.42m | 100.00 | -- | 6.67 | -- | 7.63 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 151.45m | 233.00 | -- | -- | -- | 1.19 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| CervoMed Inc | 8.08m | -4.15m | 156.33m | 8.00 | 37.05 | 21.90 | -- | 19.34 | 0.5113 | 0.5113 | 1.74 | 0.8648 | 0.6124 | -- | -- | 1,010,531.00 | -31.45 | -53.67 | -38.42 | -58.89 | -- | -- | -51.36 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| OptiNose Inc | 74.02m | -30.75m | 156.43m | 132.00 | -- | -- | -- | 2.11 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| CytoDyn Inc | 0.00 | -51.69m | 156.71m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| ProQR Therapeutics NV | 14.62m | -29.10m | 158.64m | 157.00 | -- | 4.35 | -- | 10.85 | -0.3584 | -0.3584 | 0.1801 | 0.4481 | 0.0957 | -- | -- | 93,136.34 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| P3 Health Partners Inc | 1.35bn | -67.27m | 158.69m | 400.00 | -- | 0.4089 | -- | 0.1173 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Alimera Sciences Inc | 90.22m | -22.66m | 159.79m | 159.00 | -- | 3.93 | -- | 1.77 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Rezolute Inc | 0.00 | -58.21m | 161.74m | 51.00 | -- | 2.28 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Atossa Therapeutics Inc | 0.00 | -29.69m | 163.48m | 10.00 | -- | 1.90 | -- | -- | -0.2359 | -0.2359 | 0.00 | 0.6833 | 0.00 | -- | -- | 0.00 | -28.65 | -29.97 | -29.84 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Adverum Biotechnologies Inc | 0.00 | -112.90m | 164.39m | 121.00 | -- | 0.9018 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Outlook Therapeutics Inc | 0.00 | -159.13m | 165.48m | 24.00 | -- | -- | -- | -- | -11.48 | -11.48 | 0.00 | -6.10 | 0.00 | -- | -- | 0.00 | -281.52 | -214.69 | -2,060.72 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.75 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 167.06m | 107.00 | -- | 0.6925 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Galectin Therapeutics Inc | 0.00 | -44.78m | 169.04m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 0.00 | -128.91m | 169.62m | 93.00 | -- | 163.72 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
Data as of Jun 04 2024. Currency figures normalised to Alimera Sciences Inc's reporting currency: US Dollar USD
79.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Caligan Partners LPas of 31 Mar 2024 | 16.84m | 32.16% |
| Velan Capital Investment Management LPas of 14 May 2024 | 9.43m | 18.01% |
| Stonepine Capital Management LLCas of 31 Mar 2024 | 4.05m | 7.74% |
| Boothbay Fund Management LLCas of 31 Mar 2024 | 3.20m | 6.11% |
| Altium Capital Management LPas of 31 Mar 2024 | 2.55m | 4.87% |
| Clearline Capital LPas of 31 Mar 2024 | 2.09m | 3.98% |
| AIGH Capital Management LLCas of 31 Mar 2024 | 1.52m | 2.90% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.03m | 1.97% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 494.28k | 0.94% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 470.57k | 0.90% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
